“Only buy something that you’d be perfectly happy to hold if the market shut down for 10 years.”
— Warren Buffett
DaVita Inc. (NYSE: DVA) has delivered a strong long-term share price gain over the past decade. Based on the figures below, a $10,000 investment in DVA made on 09/02/2016 and held through 09/01/2026 would have grown to $27,197.42. Because DaVita does not pay a dividend, the full return in this period came from capital appreciation rather than income or reinvestment.
That distinction matters. For a stock such as DaVita, long-term performance depends primarily on the company’s ability to expand earnings, manage capital effectively, and sustain investor confidence in its business model. The result is a useful case study in how a non-dividend-paying healthcare stock can still compound meaningfully over a full market cycle.
DVA 10-Year Return Summary
| Start date: | 09/02/2016 |
|
|||
| End date: | 09/01/2026 | ||||
| Start price/share: | $64.78 | ||||
| End price/share: | $176.14 | ||||
| Starting shares: | 154.37 | ||||
| Ending shares: | 154.37 | ||||
| Dividends reinvested/share: | $0.00 | ||||
| Total return: | 171.90% | ||||
| Average annual return: | 10.52% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $27,197.42 | ||||
In practical terms, the investment nearly tripled over the period. The annualized return of 10.52% is especially notable because compounding at that rate over a decade can materially change long-term portfolio outcomes. Starting from a relatively modest base, the gain was driven by the stock price rising from $64.78 to $176.14, while the share count remained unchanged at 154.37 because there were no dividends to reinvest.
[These numbers were computed with the Dividend Channel DRIP Returns Calculator.]
What Drove the Return?
DaVita is best known as a kidney care company with a large dialysis services business. Its long-term investment case has generally rested on the durability of demand for renal care, the scale advantages of a national provider network, and the company’s ability to convert operating performance into earnings and cash flow. Over time, the market has rewarded that combination, though not always in a straight line.
For a company like DaVita, several factors typically shape shareholder returns:
- Earnings growth: Sustained growth in profitability tends to support a higher share price over time.
- Capital allocation: When a company does not pay a dividend, management’s use of retained cash becomes even more important.
- Valuation changes: A stock’s return reflects not only business performance, but also how much investors are willing to pay for that performance.
- Industry and policy conditions: Healthcare reimbursement, regulation, and patient volume trends can materially affect long-run expectations.
Why the Lack of Dividends Matters
DaVita’s 10-year result differs from the return profile of many income-oriented healthcare stocks. Because the company paid no dividend during this measurement period, there was no contribution from yield, no reinvestment effect, and no increase in share count. That makes the math straightforward: the ending value came entirely from appreciation in the stock itself.
This also means the market’s view of future earnings power played an outsized role in the result. In dividend-paying stocks, part of the return can come from cash distributions even during flat share-price periods. In DaVita’s case, investors were relying on the underlying business to create value that would ultimately be reflected in the stock price.
Key Takeaways From This 10-Year DVA Investment
For quick reference, the main conclusions are simple:
- A $10,000 investment in DVA on 09/02/2016 grew to $27,197.42 by 09/01/2026.
- The total return was 171.90%.
- The annualized return was 10.52%.
- The return came entirely from share price appreciation, not dividends.
The broader lesson is that patient ownership can be effective when the underlying business compounds value over time. Even so, historical returns should be examined alongside the business factors that produced them. For DaVita, future performance will depend less on what the stock did over the last decade and more on how the company executes from here in a healthcare environment shaped by reimbursement trends, operating efficiency, and capital discipline.
“When you sell in desperation, you always sell cheap.” — Peter Lynch
